Strategic Advice. Proven Execution. Deep Sector Expertise.

Tom Davidson is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman. He serves on the Firm’s Executive Committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Mr. Davidson is focused on building a world class Mergers & Acquisitions business at Leerink Partners.

Over the last decade, Mr. Davidson has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.

Prior to joining the Firm in 2024, from PJT Partners, where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.

Mr. Davidson earned a B.A. in Economics from Yale University, summa cum laude and Phi Beta Kappa and an MBA from the Wharton School of the University of Pennsylvania. Mr. Davidson is a member of the Board of Trustees of the Rye Country Day School in Rye, NY. 

Dan Dubin, M.D., is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman and sits on the Firm’s Executive Committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Toby King is a Senior Managing Director in Investment Banking at Leerink Partners, focused on the Healthcare Provider continuum. With over 20 years of Healthcare Investment Banking experience, he has advised some of the industry’s leading healthcare providers and private equity firms across a wide variety of situations.

Prior to joining the Firm in 2021, from Citigroup, where Mr. King spent more than a decade, most recently as Managing Director and Head of North America Healthcare leading efforts with individual coverage across hospitals, alternate-site providers, behavioral health, outsourcing and post-acute care. Prior to Citigroup, he spent over ten years in the Healthcare Group at Merrill Lynch. Prior to investment banking, he worked at HCA’s Corporate Finance and Development group.

Mr. King earned a B.A. from Bellarmine University and an MBA from The University of Chicago, Booth School of Business.

Philip Boyd is a Senior Managing Director in Investment Banking at Leerink Partners. He has advised a wide variety of clients on mergers and acquisitions, divestitures, spin-offs, recapitalizations, leveraged buyouts, takeover defense, and capital raising.

Prior to joining the Firm in 2024, Mr. Boyd spent nearly a decade at Guggenheim Securities in the healthcare services sector, where he led strategic transactions for public and private companies. Earlier in his career, he was an associate in Citigroup’s Healthcare Investment Banking Group.

Mr. Boyd earned his B.S. in Applied Economics and Management and his MBA from Cornell University.

Ben Brown is a Senior Managing Director in Investment Banking at Leerink Partners and leads the Firm’s Pharma Services practice. With over 20 years of experience, he has executed M&A and equity transactions for clients across several verticals, including pharma outsourcing and IT, payor and provider services, healthtech, software, consulting and human capital services.

Prior to joining the Firm in 2021, Mr. Brown spent over 15 years at Baird where he was most recently a Managing Director and Head of Global Pharma Services Investment Banking. Prior to Baird, he held investment banking and private equity positions with Thomas Weisel Partners, The Halifax Group, Growth Capital Partners and Prudential Capital Group.

Mr. Brown earned a B.B.A. from Southern Methodist University (cum laude) and an MBA from Northwestern University, Kellogg School of Management.

Gabe Cavazos is a Senior Managing Director in Investment Banking at Leerink Partners. He covers East Coast and European biopharma companies and has 15+ years of transaction experience, including more than 100 transactions across M&A advisory, equity and equity linked financings.

Prior to joining the Firm in 2008, Mr. Cavazos was a member of the Mergers & Acquisitions group at J.P. Morgan. Prior to J.P. Morgan, he spent eight years in the pharmaceutical industry at Merck and Pfizer.

Mr. Cavazos earned a B.S. from The University of Michigan and his MBA from the Kellogg School of Management at Northwestern University.

Michael Clifford is a Senior Managing Director in Investment Banking at Leerink Partners, covering Healthcare Technology and Services and supporting the Firm’s Mergers & Acquisitions efforts. With more than 13 years of Healthcare Investment Banking experience, he has led the execution of strategic transactions for a variety of public and private companies on mergers & acquisitions, equity offerings (IPOs, follow-ons and private placements), acquisition financings and debt financings.

Prior to joining the Firm in 2015, Mr. Clifford worked in the Consumer and Healthcare Investment Banking Group at Wells Fargo Securities, covering healthcare technology and services verticals. Prior to Wells Fargo Securities, he worked in the Transaction Services group at PwC in New York.

Mr. Clifford earned a BSBA (cum laude) in Financial Management & Investments and Accounting from the University of Arkansas.

Jon Civitarese is a Senior Managing Director in Investment Banking at Leerink Partners.

Mr. Civitarese joined the Firm in 1995 as one of the Firm’s earliest employees. He provided advisory services to high-net-worth individuals in the Private Client Group prior to moving to Investment Banking. Since 1999, his activities have included advising public and private life science companies on strategic initiatives and equity capital financings as part of the Firm’s investment banking team. In addition to his primary banking responsibilities, he has also served as a senior member of the equity capital markets and syndicate team since 2001.

Mr. Civitarese began his career by serving in the U.S. Army as an infantry soldier, and later graduated from the University of Maine.

Grant Curry is a Senior Managing Director at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2024, Mr. Curry was most recently a Managing Director at Dyalco, specializing in mergers & acquisitions and activism defense. He has advised on a wide range of biopharma and health care transactions, including Bristol-Myers Squibb in its acquisition of Celgene, Bristol-Myers Squibb in its acquisition of MyoKardia, Novartis on its spin-off of Sandoz, Novartis in its acquisition of AveXis, Novartis in the divestment of its consumer healthcare joint venture interest to GSK, Amgen in its acquisition of Otezla, and Charles River Laboratories in its acquisition of Cognate. Prior to joining Dyalco in 2016 as one of its first employees, Grant was a member of the Global Healthcare Group of UBS.

Mr. Curry earned a B.A. from Whitman College and an MBA from The University of Chicago Booth School of Business.

Murphy Gallagher is a Senior Managing Director in Investment Banking at Leerink Partners.

Prior to joining the Firm in 2009, he was a member of the Global Healthcare Investment Banking Group at Merrill Lynch. Mr. Gallagher focuses on the Biopharma sector and has over 17 years advising companies on capital markets, mergers and acquisitions and strategic advisory assignments.

Mr. Gallagher earned a B.A. from Georgetown University.

Andrew Gitkin is a Senior Managing Director in Investment Banking at Leerink Partners.

Prior to joining the Firm in 2024, Mr. Gitkin served as a Senior Managing Director and Vice Chairman in the healthcare investment banking group at Raymond James & Associates. He brings over 25 years of healthcare-focused experience specializing in the biopharma and medical device sectors, including more than 100 transactions across M&A advisory, equity and equity linked financings. Prior to Raymond James, he served as a Managing Director and Head of West Coast Biotechnology at PiperJaffray & Company, and Senior Vice President at Moelis & Company. Mr. Gitkin’s previous experience also includes roles as a Vice President of Tavistock Life Sciences and leading a biotechnology start-up. He started his career in the Equity Research Departments of SalomonSmithBarney and UBS.

Mr. Gitkin hearned his B.B.A. from Emory University and he is a member of the UCLA Health System Board.

Tim Hotchandani is a Senior Managing Director of Healthcare Services & Technology Investment Banking.

Prior to joining the Firm in 2024, Mr. Hotchandani served as a Managing Director at Rothschild & Co, specializing in the coverage of Life Science Technology companies globally. Previously, he was a Managing Director at Deutsche Bank and began his career as an investment banking analyst at Lehman Brothers and Thomas Weisel Partners LLC.

Mr. Hotchandani earned a Bachelor of Business and Economics from the University of Wisconsin-Madison. He is also a CFA® charterholder.

Robert Jackey is a Senior Managing Director in Investment Banking at Leerink Partners and is focused on coverage for Physician Services and Healthcare Provider companies.

Prior to joining the Firm in 2021, Mr. Jackey served as a Managing Director at Citigroup, covering the alternate site / sub-acute, behavioral, clinical staffing / outsourcing, dental, hospital / acute care, patient transportation, physician organization and veterinary verticals. With over 18 years of Healthcare Investment Banking experience, he has led efforts to execute strategic transactions for a variety of public and private companies. Mr. Jackey’s advisory and execution experience spans the spectrum of traditional provider organizations through high-growth healthcare disruptors, including domestic and multinational corporations.

Mr. Jackey earned his B.S. (summa cum laude) in electrical engineering as well as an MBA from Fairleigh Dickinson University.

Dr. Anurag Jindal is a Senior Managing Director in Investment Banking at Leerink Partners covering the biopharma sector. He has over two decades of experience in the biopharma industry, as an investment banker, a consultant, and in strategic roles at a major pharmaceutical company.

Prior to joining the Firm in 2021, Dr. Jindal was a Managing Director in the Healthcare Investment Banking group at Bank of America where he focused on strategic advisory and capital markets transactions for public and private companies in the biotech sector. Prior to Bank of America, Dr. Jindal was the Deputy Head of Pharma M&A and in the Pharma Strategy Group at Novartis in Switzerland and in the Healthcare Investment Banking group at JP Morgan in both New York and San Francisco. He started his career as a Pharmaceutical Analyst at Health IQ in Los Angeles.

Dr. Jindal earned his B.A. in Molecular and Cell Biology from the University of California, Berkeley and a M.D. from the University of Southern California.

Aniket Kaloti is a Senior Managing Director in Investment Banking at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2018, Mr. Kaloti spent nearly 5 years in consulting, most recently at IQVIA, advising biopharma clients on a range of strategic projects spanning corporate finance, brand and commercial strategy, business development and M&A due diligence, and financial analysis. He has advised on a number of biopharma transactions at Leerink Partners including the sale of Decibel to Regeneron, the sale of Zogenix to UCB, and the sale of Dicerna to Novo Nordisk. Earlier in his career, Mr. Kaloti advised multiple biotech and health-tech startups, including with respect to raising capital through government grants and private investors. Prior to joining the industry, he was a post-doctoral scholar in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology.

Mr. Kaloti earned his M.B.B.S. (US M.D. Equivalent) from University of Mumbai, Masters’ in Biomedical Engineering at IIT Bombay and PhD in Neuroscience at Northwestern University.

Dan Lepanto is a Senior Managing Director in Investment Banking at Leerink Partners focused on Biopharma Mergers & Acquisitions.

Prior to joining the Firm in 2008, Mr. Lepanto spent 10 years at Cowen and Company where he executed a range of biopharma M&A transactions. He began his career in the Mergers & Acquisitions group at Wasserstein Perella. Mr Lepanto has advised on a number of biopharma and healthcare transactions over the span of his career including the sale of Dicerna to Novo Nordisk, the sale of Dermira to Eli Lilly, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.

Mr. Lepanto earned his B.S. in Finance with High Honors from Pennsylvania State University.

Michael Lindenberg is a Senior Managing Director in Investment Banking at Leerink Partners primarily focused on physician services, multi-site healthcare and alternative site subsectors, as well as developing the Firm’s financial sponsor coverage efforts. With over 14 years of healthcare services-focused investment banking experience, Mr. Lindenberg has advised a wide variety of financial sponsor and strategic clients on mergers and acquisitions, divestitures, restructurings, recapitalizations, buyouts, and capital raise transactions.

Prior to joining the Firm in 2021, Mr. Lindenberg focused on advising companies and financial sponsors across the healthcare services ecosystem at Guggenheim Securities. Prior to that, he was a Vice President in Jefferies Group’s Healthcare Investment Banking practice, having started his U.S. advisory career in the Life Sciences team of Deloitte’s Financial Advisory Services group in New York.

Mr. Lindenberg earned his Bachelor’s degree from Stellenbosch University in South Africa and his MBA from the University of Rochester in New York.

Michael Lindenberg is a Senior Managing Director in Investment Banking at Leerink Partners primarily focused on physician services, multi-site healthcare and alternative site subsectors, as well as developing the Firm’s financial sponsor coverage efforts. With over 14 years of healthcare services-focused investment banking experience, Mr. Lindenberg has advised a wide variety of financial sponsor and strategic clients on mergers and acquisitions, divestitures, restructurings, recapitalizations, buyouts, and capital raise transactions.

Prior to joining the Firm in 2021, Mr. Lindenberg focused on advising companies and financial sponsors across the healthcare services ecosystem at Guggenheim Securities. Prior to that, he was a Vice President in Jefferies Group’s Healthcare Investment Banking practice, having started his U.S. advisory career in the Life Sciences team of Deloitte’s Financial Advisory Services group in New York.

Mr. Lindenberg earned his Bachelor’s degree from Stellenbosch University in South Africa and his MBA from the University of Rochester in New York.

Sean Pitt is a Senior Managing Director in Investment Banking at Leerink Partners.

Mr. Pitt joined the Firm in 2017 and has over a decade of healthcare investment banking experience. He has advised a broad range of biopharma companies across equity and strategic advisory assignments and transactions, having worked on over 200 transactions during his career.

Mr. Pitt earned a B.S. from The University of Sydney, Australia.

Bernhard Sakmann, M.D., is a Senior Managing Director in Investment Banking at Leerink Partners covering the Medical Technology and Life Science Tools and Diagnostics sectors.

Prior to joining the Firm in 2024, Dr. Sakmann was a Senior Managing Director at Evercore, where he provided strategic and financial advice to life science companies with a focus on medical technology and life science tools and diagnostics. Prior to that, Dr. Sakmann spent over a decade in healthcare investment banking and in management consulting with Citigroup, Lehman Brothers and Oliver Wyman in New York and in London. Notable transactions for which Bernhard has been an adviser include Philips on its acquisitions of Biotelemetry and Capsule, GE on its acquisition of BK Medical and spin of GE Healthcare, Abbott on its acquisitions of St Jude Medical and Alere, Terumo on its acquisitions of Sequent Medical and Bolton Medical, Immucor on its sale to Werfen, Decipher on its sale to Veracyte, ArcherDx on its sale to Invitae, Brooks Automation on its acquisitions of Genewiz and BioStorage Technologies, among many others.

Dr. Sakmann earned a B.A. and an M.A. in Natural Sciences from Cambridge University, UK. a B.M. BCh. from Oxford University, UK, and a Doctorate in Medicine from Ludwig-Maximilians-University, Munich, Germany.

Eric Stewart is a Senior Managing Director in Investment Banking at Leerink Partners leading the Firm’s European M&A practice. He provides strategic and financial advice to clients across the pharmaceutical, biotech, medical technology, life science tools, and diagnostics sectors.

Prior to joining the Firm in 2025, Mr. Stewart was a Managing Director at Lazard were he advised Mallinckrodt on its $6.7bn merger with Endo, Calliditas Therapeutics on its $1.1bn sale to Asahi Kasei, Galderma on its $17bn IPO, Abcam on its $5.7bn sale to Danaher, Calypso on its up to $425mm sale to Novartis, Johnson & Johnson on its spin-off of Kenvue, Fresenius on its $900m joint venture with mAbxience, Syndesi on its up to $1.0bn sale to AbbVie, and UCB on its $1.9bn acquisition of Zogenix. Prior to his 15+ year career in investment banking, he began his career at Stryker Corporation.

Mr. Stewart earned a B.A. in Economics from the University of Michigan.

Brian Swanson is a Senior Managing Director in Investment Banking at Leerink Partners covering the biopharma sector.

Prior to joining the Firm in 2014, Mr. Swanson focused on strategy and operations for companies in the healthcare and technology sectors at PwC. He has executed more than 100 M&A and capital markets transactions for public and private biopharma companies.

Mr. Swanson earned a B.S. from Stanford University and an MBA from Cornell University.

Jason Truman is a Senior Managing Director in Investment Banking at Leerink Partners focused on Biopharma Mergers & Acquisitions. He brings over 20 years of investment banking experience, where he advised a wide variety of domestic and international biopharma clients in connection with mergers and acquisitions, divestitures, spin-offs/split-offs, takeover defense, proxy contests and capital raising.

Prior to joining the Firm in 2024, Mr. Truman was a Senior Managing Director in the Biopharma Investment Banking Practice at Guggenheim Securities. Prior to that, Mr. Truman specialized in mergers and acquisitions in the biopharma space working at firms including Credit Suisse and Morgan Stanley.

Mr. Truman earned a B.B.A. from the Ross School of Business at the University of Michigan and his MBA from the Darden School of Business at the University of Virginia. He is a member of the Life Science Institute Leadership Council at the University of Michigan.

Byron Webster is a Senior Managing Director in Investment Banking at Leerink Partners and is focused on the Specialty Pharmaceuticals sector. He has over 16 years of experience advising pharmaceutical companies on M&A, private and public financing assignments.

Prior to joining the Firm in 2015, Mr. Webster was a Vice President in the Healthcare Group at Lazard. He began his career at Wells Fargo Securities.

Mr. Webster earned a B.A. summa cum laude from Wake Forest University.

Justin Reed is a Managing Director in Investing Banking at Leerink Partners where he is focused on advising companies in the medical device sector on M&A and public and private equity offerings.

Prior to joining the Firm in 2024, Mr. Reed was a Managing Director in the strategic advisory business at Evercore where he advised on many transactions across the medical device sector including GE Healthcare’s spin from GE, GE’s acquisition of BK Medical, Lunit’s acquisition of Volpara, Philips’ acquisition of Biotelemetry and Capsule, SHINE Technologies acquisition of Phoenix, Abbott on the sale of Angio-Seal to Terumo and the sale of Epocal to Siemens Healthineers, and Terumo’s acquisition of Sequent medical. Mr. Reed was previously the founder of several medical device companies and holds multiple patents and academic publications for medical device technologies.

Mr. Reed earned his B.S. in Pysics from the University of Washington, and his MBA from Berkeley Haas School of Business, Master of Science in Physics from the University of Washington.

Rahul Chaudhary is a Senior Managing Director and Head of Equity Capital Markets at Leerink Partners. He is responsible for the origination and execution of all varieties of public and private equity offerings, including IPOs, follow-ons and private investments in public equity. Since joining the Firm, Mr. Chaudhary has led more than 500 book run offerings, including more than 150 IPOs.

Prior to joining the Firm in 2009, Mr. Chaudhary was responsible for the origination and execution of healthcare equity and equity-linked transactions on the ECM team at Merrill Lynch. He began his career at Merrill Lynch in 2004 in the investment banking group, centered on the consumer sector, where he worked on a variety of equity, debt and M&A assignments.

Mr. Chaudhary earned a bachelor’s degree in Finance from the University of Illinois.

Jack Bannister is a Senior Managing Director on the Equity Capital Markets team at Leerink Partners. He partners with healthcare and life sciences companies to raise capital and position them for success in the public markets.

Prior to joining the Firm in 2021, Mr. Bannister served as Vice President of the Healthcare Equity Capital Markets team at Goldman Sachs. He began his career as an Equity Analyst with T. Rowe Price in Baltimore.

Mr. Bannister earned a B.A. from the University of North Carolina at Chapel Hill and an MBA from the University of Virginia Darden School of Business.

Patrick Morley is a Senior Managing Director in Leerink Partners’ Equity Capital Markets group, advising private and public healthcare companies on the optimal strategy and tactics to achieve their financing goals. He joined the Firm in 2011 as a member of the Healthcare Investment Banking group before transitioning to his current role.

He earned bachelor’s degrees in Industrial Engineering and Finance from Lehigh University, and is a CFA charterholder.

Prasanth “Burri” Rao-Kathi is a Senior Managing Director at Leerink Partners and leads the Firm’s Convertibles business.

Prior to joining the Firm in 2016, he was the Head of Equity-Linked (Convertibles) Origination in the Equity Capital Markets group at Bank of America Merrill Lynch. Mr. Rao-kathi joined the ECM group at Merrill Lynch in 1999 and worked on a number of Merrill Lynch’s landmark convertible innovations over the last 15 years including: Contingent Conversion, Contingent Payment, Bond Hedges, HiPrs, Collateralization, Simultaneous Bond and Stock Repurchases, and Prepaid Forwards in conjunction with new issues. Prior to joining Merrill Lynch, he worked in Fixed Income Swaps Marketing and Trading and Corporate Finance / Mergers and Acquisitions at J.P. Morgan.

Mr. Rao-Kathi earned degrees in Finance and International Business with a minor in English from Georgetown University (Magna Cum Laude) and his MBA in Finance from the Wharton School of Business at the University of Pennsylvania.

Richard Mei is a Senior Managing Director at Leerink Partners focused on Debt Capital Markets.

Prior to joining the Firm in 2018, Mr. Mei was a member of the corporate finance team at Regeneron Pharmaceuticals. He has over 16 years of experience advising companies on convertible financing, equity derivatives, and liability management. Prior to Regeneron, he spent over a decade at Bank of America Merrill Lynch in various investment banking and capital markets roles.

Mr. Mei earned a B.S. from the University of California at Berkeley and an MBA from New York University.

Peter M. Fry is a Senior Managing Director at Leerink Partners leading our Alternative Equities business. He has over 25 years of experience on both sell-side & buy-side and has built one of the market-leading franchises in At-The-Market (ATM) offerings.

Prior to joining the Firm in 2020, Mr. Fry was a Managing Director and Head of Alternative Equities at H.C. Wainwright & Co. He held similar leadership roles at Guggenheim Securities and Burrill & Company. Earlier in his career, he spent eight years as Senior Investment Officer at Kingsbridge Capital and was a Senior Healthcare Banker and Head of Public/Private Placements at Investec Inc. and RBC Capital Markets.

Mr. Fry earned a B.A. in Economics and Finance from Bucknell University.

Seth M. Christian is a Senior Managing Director at Leerink Partners leading trading for our Alternative Equities business. He has over 20 years of buy-side experience and has leveraged his healthcare fund expertise to maximize trading opportunities for one of the top franchises in At-The-Market (ATM) offerings.

Prior to joining the Firm in 2020, Mr. Christian was a Managing Director and Head of Trading and Capital Markets at Broadfin Capital. He had a similar role and was on the launch team at the healthcare-focused fund, March Altus Capital. Earlier in his career, Mr. Christian held trading roles at Angel Lane Principal Strategy, Catapult/Millenium Partners and Sapphire Capital.

Mr. Christian earned a B.A. in Economics from Tufts University.

Tom Davidson is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman. He serves on the Firm’s Executive Committee, where he shares responsibility for shaping the long-term strategy and driving the growth of Leerink Partners. Drawing on over three decades of experience advising CEOs and boards in the biopharma sector, Mr. Davidson is focused on building a world class Mergers & Acquisitions business at Leerink Partners.

Over the last decade, Mr. Davidson has been one of the most active M&A advisors in the biopharma sector globally. Notable recent deals include Amgen’s $27.3 billion acquisition of Horizon Therapeutics, the largest life sciences transaction of 2022, CSL’s $11.7 billion acquisition of Vifor, the largest life sciences transaction of 2021 and the $50 billion combination of Mylan and Upjohn which closed in 2020. In addition to his recurring work with some of the largest companies in the sector, he focuses a majority of his practice on working with emerging growth biotechnology companies, including Crown Laboratories, Novavax and Protagonist Therapeutics, each during 2024.

Prior to joining the Firm in 2024, from PJT Partners, where he was a founding partner of the firm. He previously served as Vice Chairman and Global Co-Head of Healthcare Investment Banking at Credit Suisse, where he was a member of the Global Investment Banking Operating Committee and as a Managing Director at Merrill Lynch.

Mr. Davidson earned a B.A. in Economics from Yale University, summa cum laude and Phi Beta Kappa and an MBA from the Wharton School of the University of Pennsylvania. Mr. Davidson is a member of the Board of Trustees of the Rye Country Day School in Rye, NY. 

Dan Dubin, M.D., is the Co-President of Leerink Partners, Co-Head of Global Investment Banking, Vice Chairman and sits on the Firm’s Executive Committee.

For over 25 years, Dr. Dubin has advised life sciences companies and investors and has executed numerous public offering, private placement, partnership, and M&A transactions for clients. In 1996, he co-founded MEDACorp, a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. In 2001, Dr. Dubin merged MEDACorp into Leerink Partners and joined its Board of Directors and Executive Committee. He has served as a science and strategy board member for Stiefel/GSK, director of Living Proof, director of Olivo Lab, and Chairman of MetaWorks which was sold to UBC in 2005.

Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in Medicine and a residency in Dermatology at the Massachusetts General Hospital. He was an Instructor in Dermatology at Harvard Medical School and held a staff appointment at the Brigham and Women’s Hospital where he was the Ambulatory Medical Director of Clinical Dermatology and a member of the Clinical Executive Committee. He has published over 30 manuscripts in peer reviewed publications and performed a NIH training fellowship at the Harvard Skin Disease Research Center.

Christine Del Corsano serves as the Global Chief Operating Officer of Investment Banking at Leerink Partners. She brings over 25 years of experience in finance and healthcare investment banking.

Mrs. Del Corsano rejoined the Firm in 2025, after serving as Chief Financial Officer of Enavate Sciences, where she was responsible for finance and operations, and partnered with executive leadership on corporate strategy and supporting portfolio company operations.

During her earlier tenure at Leerink Partners, Mrs. Del Corsano was a Managing Director and Business Manager, responsible for managing the overall operations of the department including strategic planning, financial and business reporting and analytics, people management and recruiting. Prior to Leerink Partners, she held senior leadership positions at Merrill Lynch, including COO of the Healthcare, Energy & Power, and Technology Investment Banking groups.

Mrs. Del Corsano earned her B.S. in Accounting from St. John’s University.